title: Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion.
authors.affiliation: Mater Hospital, Brisbane, Queensland, Australia. jakob.begun@mater.uq.edu.au.|Mater Research Institute, Brisbane, Queensland, Australia. jakob.begun@mater.uq.edu.au.|University of Queensland School of Medicine, Brisbane, Queensland, Australia. jakob.begun@mater.uq.edu.au.
authors.forename: Jakob
authors.initials: J
authors.lastname: Begun
mesh_terms: D000293:Adolescent; D001379:Azathioprine / Q000008:administration & dosage* / Q000009:adverse effects; D003424:Crohn Disease / Q000628:therapy*; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D004750:Enteral Nutrition; D006150:Guanine Nucleotides / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab / Q000008:administration & dosage / Q000009:adverse effects; D016399:Lymphoma, T-Cell / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D013873:Thionucleotides / Q000008:administration & dosage
chemical_list: D006150:Guanine Nucleotides; D007166:Immunosuppressive Agents; D013873:Thionucleotides; C003964:6-thioguanylic acid; D000069285:Infliximab; D001379:Azathioprine; D008727:Methotrexate